Growth momentum Anika is expanding in the osteoarthritis pain management and regenerative orthopedics space with growing Q2 revenue, expanded gross margins, and strong adjusted EBITDA, signaling opportunities to align with distributors and regional partners in high-growth markets.

International push Strength in international commercial growth presents a pathway to collaborate with global distributors and OEMs seeking proven HA-based solutions and early intervention products to broaden their orthopedic portfolios in new regions.

Regenerative focus With emphasis on regenerative solutions and minimally invasive products, there is potential to cross-sell integrated care pathways and companion devices to clinics adopting cutting-edge OA therapies and soft-tissue preservation strategies.

Operational edge Recent operational transformation and improved manufacturing efficiency underpin reliability and margin resilience, enabling sales teams to position Anika as a dependable supplier to large healthcare systems and OEM partners seeking stable supply chains.

Strategic personnel New talent acquisitions and inducement grants indicate a growth-oriented culture that can support expanded field teams, clinical training programs, and joint marketing initiatives with key KOLs to drive adoption of Monovisc, Orthovisc, Integrity, and related products.